Background/Aims: Concurrent treatment with methotrexate (MTX) and enzyme-inducing antiepileptic drugs including phenobarbital (PB) reduces the efficacy of MTX chemotherapy in cancer patients. We have shown that Reduced folate carrier (Rfc1)-mediated uptake of MTX, an essential determinant of MTX chemotherapy, is significantly reduced by PB via protein kinase C (PKC). However, whether PB treatment affects Rfc1 activity through regulation of carrier protein stability and the mechanisms involved remain unclear. Methods/Results: Protein turnover assays using hepatocytoma cells demonstrated that Rfc1 is a long-lived protein that is mainly degraded by the ubiquitin-proteasome proteolytic pathway under basal conditions. Pretreatment with PB significantly reduced Rfc1-mediated MTX uptake and shortened the carrier protein half-life. This effect was abolished by the specific PKC inhibitor Gö6976. Inhibition of proteasomes with MG-132 significantly elevated Rfc1 protein levels and induced colocalization of Rfc1 and ubiquitin particularly in submembranous cellular compartments. Finally, we demonstrated that PB treatment resulted in enhanced levels of Rfc1 polyubiquitin conjugates. Conclusions: Our results demonstrate that PB treatment causes downregulation of Rfc1 activity through PKC-dependent accelerated degradation of the Rfc1 protein by the ubiqutin-proteasome pathway. This regulatory mechanism may therefore involve clinically relevant drug resistance in patients concurrently receiving MTX and enzyme-inducing antiepileptic drugs.

Keywords:
Drug resistance, Methotrexate, Antiepileptic drugs, Reduced folate carrier, Transport, Regulation, Protein degradation, Ubiquitin-proteasome pathway
1.
Honscha W, Dötsch KU, Thomsen N, Petzinger E: Cloning and functional characterization of the bile acid-sensitive methotrexate carrier from rat liver cells. Hepatology 2000;31:1296–1304.
2.
Matherly LH, Goldman ID: Membrane transport of folates. Vitam Horm 2003;66:403–456.
3.
Kneuer C, Honscha KU, Honscha W: Rat reduced-folate carrier-1 is localized basolaterally in MDCK kidney epithelial cells and contributes to the secretory transport of methotrexate and fluoresceinated methotrexate. Cell Tissue Res 2005;320:517–524.
4.
Balamurugan K, Said HM: Role of reduced folate carrier in intestinal folate uptake. Am J Physiol Cell Physiol 2006;291:C189–C193.
5.
Josting A, Diehl V, Engert A: Methotrexat: Pharmakologie, Toxizität und Rescuemassnahmen bei hochdosierter Behandlung. Onkologe 1998;4:974–985.
6.
Tageja N, Valent J, Bentley G, Zonder J: Precursor T cell acute lymphoblastic lymphoma presenting as bilateral facial nerve palsy. Chemotherapy 2010;56:258–260.
7.
Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, Cowan KH: Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790–3974.
8.
Dixon KH, Lampher BC, Chiu J, Kelley K, Cowan KH: A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994;269:17–20.
9.
Williams FM, Murray RC, Underhill TM, Flintoff WF: Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J Biol Chem 1994;269:5810–5816.
10.
Ferguson PL, Flintoff WF: Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J Biol Chem 1999;274:16269–16278.
11.
Honscha W, Petzinger E: Characterization of the bile acid sensitive methotrexate carrier of rat liver cells. Naunyn Schmiedebergs Arch Pharmacol 1999;359:411–419.
12.
Sierra EE, Goldman ID: Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol 1999;26:11–23.
13.
Kneuer C, Honscha W: The H(+)-dependent reduced folate carrier 1 of humans and the sodium-dependent methotrexate carrier-1 of the rat are orthologs. FEBS Lett 2004;566:83–86.
14.
Horne DW: Na+ and pH dependence of 5-methyltetrahydrofolic acid and methotrexate transport in freshly isolated hepatocytes. Biochim Biophys Acta 1990;1023:47–55.
15.
Gewirtz DA, White JC, Randolph JK, Goldman ID: Transport, binding, and polyglutamation of methotrexate in freshly isolated rat hepatocytes. Cancer Res 1980;40:573–578.
16.
Rajgopal A, Sierra EE, Zhao R, Goldman ID: Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 2001;281:C1579-C1586.
17.
Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F: Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. Chemotherapy 2008;54:166–175.
18.
Åstrand B: Avoiding drug-drug interactions. Chemotherapy 2009;55:215–220.
19.
Tibussek D, Distelmaier F, Schönberger S, Göbel U, Mayatepek E: Antiepileptic treatment in paediatric oncology – an interdisciplinary challenge. Klin Padiatr 2006;218:340–349.
20.
Kim SR, Park CH, Park S, Park JO, Lee J, Lee SY: Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. Chemotherapy 2010;56:313–317.
21.
Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE: Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285–290.
22.
Halwachs S, Kneuer C, Honscha W: Downregulation of the reduced folate carrier transport activity by phenobarbital-type cytochrome P450 inducers and protein kinase C activators. Biochim Biophys Acta 2007;1768:1671–1679.
23.
Halwachs S, Schäfer I, Seibel P, Honscha W: Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of reduced folate carrier transport activity. Leukemia 2009;23:1087–1097.
24.
Knecht E, Aguado C, Cárcel J, Esteban I, Esteve JM, Ghislat G, Moruno JF, Vidal JM, Sáez R: Intracellular protein degradation in mammalian cells: recent developments. Cell Mol Life Sci 2009;66:2427–2443.
25.
Sheldon AL, González MI, Krizman-Genda EN, Susarla BT, Robinson MB: Ubiquitination-mediated internalization and degradation of the astroglial glutamate transporter, GLT-1. Neurochem Int 2008;53:296–308.
26.
Miranda M, Sorkin A: Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv 2007;7:157–167.
27.
Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998;8:397–403.
28.
Keitel V, Nies AT, Brom M, Hummel-Eisenbeiss J, Spring H, Keppler D: A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003;284:G165–G174.
29.
Zhang Z, Wu JY, Hait WN, Yang JM: Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 2004;66:395–403.
30.
Malik B, Price SR, Mitch WE, Yue Q, Eaton DC: Regulation of epithelial sodium channels by the ubiquitin-proteasome proteolytic pathway. Am J Physiol Renal Physiol 2006;290:F1285–F1294.
31.
Meinnel T, Serero A, Giglione C: Impact of the N-terminal amino acid on targeted protein degradation. Biol Chem 2006;387:839–851.
32.
Marchant JS, Subramanian VS, Parker I, Said HM: Intracellular trafficking and membrane targeting mechanisms of the human reduced folate carrier in mammalian epithelial cells. J Biol Chem 2002;277:33325–33333.
33.
McDonald JH: G-test for goodness-of-fit; in McDonald (ed): Handbook of Biological Statistics. Baltimore, Sparky House Publishing, 2009, vol 2, pp 46–51.
34.
Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schächtele C, Klemm K, Grunicke H: Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 1996;74:897–905.
35.
Tzameli I, Pissios P, Schuetz EG, Moore DD: The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 2000;20:2951–2958.
36.
Zhou P: Determining protein half-lives. Methods Mol Biol 2004;284:67–77.
37.
Halwachs S, Kneuer C, Honscha W: Endogenous expression of liver-specific drug transporters for organic anions in the rat hepatocytoma fusion cell line HPCT-1E3. Eur J Cell Biol 2005;84:677–686.
38.
Martiny-Baron G, Kazanietzs MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marmé D, Schächtele C: Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem 1993;268:9194–9197.
39.
Seglen PO, Grinde B, Solheim AE: Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine and leupeptin. Eur J Biochem 1979;95:215–225.
40.
Xia X, Roundtree M, Merikhi A, Lu X, Shentu S, Lesage G: Degradation of the apical sodium-dependent bile acid transporter by the ubiquitin-proteasome pathway in cholangiocytes. J Biol Chem 2004;279:44931–44937.
41.
Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 1998;429:179–182.
42.
Kruh GD, Belinsky MG: The MRP family of drug efflux pumps. Oncogene 2003;22:7537–7552.
43.
Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID: Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917–928.
44.
Inoue K, Nakai Y, Ueda S, Kamigaso S, Ohta KY, Hatakeyama M, Hayashi Y, Otagiri M, Yuasa H: Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am J Physiol Gastrointest Liver Physiol 2008;294:G660–G668.
45.
Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID: The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 2008;74:854–862.
46.
Biswal BK, Verma RS: Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells. J Biochem 2009;146:693–703.
47.
Zhao R, Hanscom M, Goldman ID: The relationship between folate transport activity at low pH and reduced folate carrier function in human Huh7 hepatoma cells. Biochim Biophys Acta 2005;1715:57–64.
48.
Chandra P, Brouwer KL: The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004;21:719–735.
49.
Sadlish H, Williams FM, Flintoff WF: Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. Biochem J 2002;364:777–786.
50.
Riva M, Landonio G, Defanti CA, Siena S: The effect of anticonvulsant drugs on blood levels of methotrexate. J Neurooncol 2000;48:249–250.
51.
van der Laan BF, Jansen G, van Gestel JA, Schornagel JH, Hordijk GJ: Membrane transport of methotrexate in a squamous carcinoma cell line adapted to low folate concentrations. Anticancer Res 1991;11:1265–1268.
52.
Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH: Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999;274:10388–10394.
53.
Hicke L, Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003;19:141–172.
54.
Traub LM, Kornfeld S: The trans-Golgi network: a late secretory sorting station. Curr Opin Cell Biol 1997;9:527–533.
55.
Leontieva OV, Black JD: Identification of two distinct pathways of protein kinase C alpha down-regulation in intestinal epithelial cells. J Biol Chem 2004;279:5788–5801.
56.
Chen D, Gould C, Garza R, Gao T, Hampton RY, Newton AC: Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J Biol Chem 2007;282:33776–33787.
57.
Keenan C, Kelleher D: Protein kinase C and the cytoskeleton. Cell Signal 1998;10:225–232.
58.
Chakraborty S, Kanakasabai S, Bright JJ: Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells. Br J Cancer 2011;104:448–459.
59.
Osabe M, Sugatani J, Takemura A, Yamazaki Y, Ikari A, Kitamura N, Negishi M, Miwa M: Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation. Biochem Biophys Res Commun 2008;369:1027–1033.
60.
Siest G, Jeannesson E, Marteau JB, Samara A, Marie B, Pfister M, Visvikis-Siest S: Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008;36:182–189.
61.
Kawai M, Chen J, Cheung CY, Chang TK: Transcript profiling of cytochrome P450 genes in HL-60 human leukemic cells: upregulation of CYP1B1 by all-trans-retinoic acid. Mol Cell Biochem 2003;248:57–65.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.